Literature DB >> 1664129

Evaluation of herpes simplex virus vaccines in animals: the guinea pig vaginal model.

L R Stanberry1.   

Abstract

The guinea pig model of genital herpes has proved useful for the evaluation of experimental herpes simplex virus vaccines. The model shares many of the features of genital herpes in humans, including a natural route of inoculation that results in self-limiting primary vulvovaginitis. Latent infection is established in sensory ganglia, and animals experience both spontaneous and ultraviolet radiation-induced recurrence of infection. Many humoral, cellular, and cytokine responses to herpes simplex virus type 2 infection in the guinea pig have been characterized. Both inactivated subunit immunogens and live, attenuated virus have been shown to afford some protection against primary disease, although they generally do not prevent acute viral replication or the establishment of latency. Because latently infected guinea pigs experience recurrent infections, this model has been used to explore immunotherapeutic approaches to the control of recurrent disease. With the development of more defined immunologic reagents, this model should prove useful for exploring the immune responses that are important in the control of primary, latent, and recurrent herpes simplex virus type 2 infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1664129     DOI: 10.1093/clind/13.supplement_11.s920

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  13 in total

1.  Development of an anti-guinea pig CD4 monoclonal antibody for depletion of CD4+ T cells in vivo.

Authors:  Brianne N Banasik; Clarice L Perry; Celeste A Keith; Nigel Bourne; Hubert Schäfer; Gregg N Milligan
Journal:  J Immunol Methods       Date:  2019-08-14       Impact factor: 2.303

2.  Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.

Authors:  Xavier Dervillez; Chetan Gottimukkala; Khaled W Kabbara; Chelsea Nguyen; Tina Badakhshan; Sarah M Kim; Anthony B Nesburn; Steven L Wechsler; Lbachir Benmohamed
Journal:  Future Virol       Date:  2012-04-01       Impact factor: 1.831

3.  Increased Frequency of Virus Shedding by Herpes Simplex Virus 2-Infected Guinea Pigs in the Absence of CD4+ T Lymphocytes.

Authors:  Nigel Bourne; Clarice L Perry; Brianne N Banasik; Aaron L Miller; Mellodee White; Richard B Pyles; Hubert Schäfer; Gregg N Milligan
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

Review 4.  Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?

Authors:  Gargi Dasgupta; Lbachir BenMohamed
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

5.  Recurrent vaginal shedding of herpes simplex type 2 virus in the mouse and effects of antiviral therapy.

Authors:  Nicholas Farley; David I Bernstein; Fernando J Bravo; Julie Earwood; Nancy Sawtell; Rhonda D Cardin
Journal:  Antiviral Res       Date:  2010-02-16       Impact factor: 5.970

6.  Detection of herpes simplex virus type 2 (HSV-2) -specific cell-mediated immune responses in guinea pigs during latent HSV-2 genital infection.

Authors:  Clarice L Perry; Brianne N Banasik; Summer R Gorder; Jingya Xia; Sarah Auclair; Nigel Bourne; Gregg N Milligan
Journal:  J Immunol Methods       Date:  2016-09-19       Impact factor: 2.303

7.  Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes.

Authors:  D I Bernstein; L R Stanberry; S Sacks; N K Ayisi; Y H Gong; J Ireland; R J Mumper; G Holan; B Matthews; T McCarthy; N Bourne
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs.

Authors:  David I Bernstein; Nicholas Farley; Fernando J Bravo; Julie Earwood; Monica McNeal; Jeff Fairman; Rhonda Cardin
Journal:  Vaccine       Date:  2009-10-24       Impact factor: 3.641

9.  Intravaginal administration of herpes simplex virus type 2 to mice leads to infection of several neural and extraneural sites.

Authors:  Margaret B Parr; Earl L Parr
Journal:  J Neurovirol       Date:  2003-12       Impact factor: 2.643

Review 10.  Prospects and perspectives for development of a vaccine against herpes simplex virus infections.

Authors:  Shane C McAllister; Mark R Schleiss
Journal:  Expert Rev Vaccines       Date:  2014-07-31       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.